September 9, 2014 | Hyperion Therapeutics has cancelled its acquisition of Israeli company Andromeda Biotech. The latter company is developing a treatment for Type I diabetes called DiaPep277. According to reports, Hyperion canceled the acquisition after discovering evidence that Andromeda employees falsified the drug’s clinical trial results. The acquisition was valued at hundreds of millions of dollars based on the approval and successful marketing of the drug. “Globes” reports that Andromeda was not directly informed that the acquisition was canceled. Andromeda Biotech was founded in 2007 and is headed by CEO Dr. Shlomo Dagan.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

$10M For Cyber Company That Protects Small Businesses
January 31, 2023

Phone-Block Technology For School Bus Drivers
January 31, 2023

Israeli Patients Can Now WhatsApp Their Doctor
January 31, 2023

People With Autism Experience Higher Intensity Pain
January 30, 2023
Facebook comments